Efficacy and safety of combination therapy Ezetimibe 10/rosuvastatin 40 in Egyptian patients at very high risk of atherosclerotic cardiovascular disease
In Egyptian patients at very high risk of ASCVD, the combination of Ezetimibe 10 mg/Rosuvastatin 40 mg over 12 weeks demonstrated substantial LDL-C reduction and high attainment of ESC targets, with an acceptable safety profile.
Authors
- Mahmoud Hassanein (ORCID: https://orcid.org/0000-0001-6575-8371)
- Tarek El Zawawy
- Samir Rafla (ORCID: https://orcid.org/0000-0001-8688-6532)
- Amr Zaki (ORCID: https://orcid.org/0000-0002-7619-7474)
- Mohamed Sobhy (ORCID: https://orcid.org/0000-0001-8575-3498)
- Amr Kamal (ORCID: https://orcid.org/0000-0002-1579-3723)
- Mohamed Sadaka
- Sherif Wagdy Ayad (ORCID: https://orcid.org/0000-0002-1737-0142)
- Hala Mahfouz Badran (ORCID: https://orcid.org/0000-0001-5231-750X)
- Ahmed Mokhtar (ORCID: https://orcid.org/0000-0001-6414-4968)
- Mohamed Loutfi (ORCID: https://orcid.org/0000-0002-6054-0952)
- ZEOS investigator group
Institutions
- Menoufia University (EG)
- Alexandria University (EG)
Publication Details
- Journal
- The Egyptian Heart Journal
- Published
- 2025-06-11
- DOI
- https://doi.org/10.1186/s43044-025-00655-x
- Citations
- 1
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 2.01